Related Experiment Video
Updated: Jun 16, 2026
04:44
Imaging Features of Systemic Sclerosis-Associated Interstitial Lung Disease
Published on: June 16, 2020
[Interstitial lung disease and lung cancer]
Nobuhisa Ishikawa1, Nobuoki Kohno
1Department of Molecular and Internal Medicine, Graduate School of Biomedical Sciences, Hiroshima University, Hiroshima, Japan.
Gan to Kagaku Ryoho. Cancer & Chemotherapy
|January 21, 2010
Summary
Interstitial lung diseases (ILDs), particularly idiopathic pulmonary fibrosis (IPF), increase lung cancer risk. The KL-6 marker, used for ILD and lung cancer, shows potential for prognosis and therapeutic targeting.
Area of Science:
- Pulmonary Medicine
- Oncology
- Immunology
Context:
- Interstitial lung diseases (ILDs) encompass over 200 conditions, including idiopathic pulmonary fibrosis (IPF), the most common and aggressive form.
- ILDs, especially IPF, are linked to an increased risk of developing lung cancer due to chronic inflammation and impaired tissue repair.
- The KL-6 glycoprotein (MUC1) is a known marker for interstitial pneumonia and lung adenocarcinoma.
Purpose:
- To explore the link between ILDs and lung cancer pathogenesis.
- To investigate the role of the KL-6 marker and its auto-antibodies in ILDs and lung cancer.
- To assess the therapeutic potential of anti-KL-6 monoclonal antibodies (mAbs).
Summary:
- ILDs, characterized by inflammation and aberrant repair, may promote genetic errors leading to lung cancer.
- KL-6, a tumor-associated antigen, is a sensitive marker for ILDs and shows potential as a lung cancer marker.
- Natural auto-antibodies against KL-6 correlate with good prognoses in non-small cell lung cancer patients and anti-KL-6 mAbs exhibit anti-cancer activity.
Impact:
- This research highlights the complex relationship between ILDs and lung cancer, suggesting shared underlying mechanisms.
- KL-6 and its auto-antibodies may serve as valuable biomarkers for early detection, prognosis, and therapeutic monitoring in both ILDs and lung cancer.
- Anti-KL-6 mAb-mediated immune modulation offers a potential therapeutic strategy for lung cancer, particularly in the context of ILDs.
Related Concept Videos
01:17Other Pulmonary Disorders
Respiratory disorders encompass a range of conditions with varying levels of severity. Asthma, marked by chronic airway inflammation and hypersensitivity, is one such condition. It can lead to airway obstruction due to factors like bronchial spasms, mucosal edema, increased mucus secretion, or epithelial damage. Asthma triggers are diverse, ranging from allergens to emotional upset, and treatment focuses on both immediate relief through bronchodilators and long-term inflammation suppression.
01:25Chronic Obstructive Pulmonary Disease-III: Symptoms and Complications.
Understanding the variety of primary symptoms and systemic complications that characterize chronic obstructive pulmonary disease (COPD) is crucial for healthcare professionals.
Symptoms of COPD can be classified as primary or systemic. Primary symptoms relate to reduced airflow, while systemic or extrapulmonary symptoms relate to COPD's broader impact on the body.
Primary Symptoms of COPD:
Symptoms of COPD can be classified as primary or systemic. Primary symptoms relate to reduced airflow, while systemic or extrapulmonary symptoms relate to COPD's broader impact on the body.
Primary Symptoms of COPD:
01:24Chronic Obstructive Pulmonary Disease III: Chronic Bronchitis Features
Chronic bronchitis is a key phenotype of chronic obstructive pulmonary disease (COPD), characterized by airway-centered inflammation and mucus overproduction. It develops from long-term exposure to harmful particles or gases, most commonly cigarette smoke, which triggers a persistent inflammatory response.Cellular and Structural ChangesInflammation initially affects the large bronchi and later the smaller airways, with infiltration by immune cells, including neutrophils, macrophages, and...
01:20Chronic Obstructive Pulmonary Disease-II: Pathophysiology
Chronic Obstructive Pulmonary Disease (COPD) pathophysiology is intricate and multifaceted, involving a complex interplay of physiological processes. Understanding these mechanisms is crucial for effectively managing and treating COPD. Here is an in-depth look at the critical elements in the pathophysiology of COPD:
Chronic Inflammation
Chronic Inflammation
01:13Pleura of the Lungs
The lungs are nestled in a cavity, shielded by the pleura. The pleura, a form of serous membrane, wraps around each lung. This membrane arrangement consists of two layers: the visceral and parietal pleurae. The visceral pleura lines the surface of the lungIn contrast, the parietal pleura is the outer layer and contacts to the thoracic wall, the mediastinum, and the diaphragm. The hilum is the point of connection between the visceral and parietal layers. The space between the parietal and...
01:20Chronic Obstructive Pulmonary Disease-I: Introduction
Chronic Obstructive Pulmonary Disease (COPD) is a long-lasting respiratory condition requiring continuous attention and care. It is a progressive lung disease that leads to breathing challenges due to airflow obstruction. It manifests as persistent respiratory symptoms and restricted airflow resulting from abnormalities in the airways and alveoli, usually due to long-term exposure to harmful particles or gases. COPD mainly consists of two primary conditions: emphysema and chronic bronchitis.